Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models.

Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models.

<h4>Introduction</h4>Combination therapy for acute lymphoblastic leukemia (ALL) is highly effective but results in significant toxicity including osteonecrosis. Asparaginase is known to potentiate both the antileukemic and osteonecrosis-inducing effects of dexamethasone. The schedule of...

Full description

Bibliographic Details
Main Authors: Seth E Karol, Laura J Janke, John C Panetta, Laura B Ramsey, Xiangjun Cai, Monique A Payton, David A Jenkins, William E Evans, Mary V Relling
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0216328

Internet

https://doi.org/10.1371/journal.pone.0216328

Similar Items